Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments

11 Mar 2025
www.businesswire.com
Cell Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino and Matricelf (TASE: MTLF) announced today a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies.
Nebula™, Cellino’s proprietary closed-cassette biomanufacturing system, is designed to produce high-quality induced pluripotent stem cells (iPSCs) at scale with unparalleled consistency and sterility. This innovation allows for on-demand, contamination-free iPSC production, bringing regenerative medicine closer to real-world clinical application.
As a key milestone, Cellino has successfully manufactured and delivered autologous iPSC lines from four donors to Matricelf, a biotech company developing regenespinal cord injuryor spinal cord injCellinotricelf’s approach integrates an extracellular matrix-based hydrogel derived from the patient’s own omentum, facCellinong precise cell differentiation and tissue formation while eliminating the need for immunosuppression.
MatricelfCellinow transformed Cellino-generated iPSCs into functional neural tissues, demonstrating synchronized electrical activity—a hallmark of functional neural networks. Rigorous industry-standard assays confirmed key neural characteristics, including genetic and protein neural marker expression of engineered tissues with Cellino’s iPSCs, with results comparable to Matricelf’s own iPSC-derived tissues.
With the goal of redCellino treatment paradigms for spinal cord injury, Matricelf plans to file an InvestigationalMatricelf (IND) application next year to bring its autologous iPSC-spinal cord injurytoMatricelf trials. This transformative approach addresses an urgent unmet need, potentially restoring function for millions of patients worldwide.
“Collaboration on this international scale is a vital step toward our vision of a fully autologous regenerative therapy for spinal cord injury,” said Gil Hakim, CEO of Matricelf. “Matricelf’s innovative platform, in combination with Cellino’s Nebula™ technology, is setting new standards in scalable patient-specific tissue engineering, bringing us closer to real-world applications of regenerative medicine.”
“The ability to produce high-quality, patient-specifspinal cord injuryisMatricelfo revolutionize regenerative medicine,” said Marinna Madrid, Ph.D., Co-Founder and Chief Product Officer, Cellino. “Our collaboration with Matricelf exemplifies how international collaboration can accelerate innovation and expand access to life-changing therapies.”
This collaboration highlights both companies' commitment to harnessing advanced technologies - ranging from AI-driven automaspinal cord injuryughput biomanufacturing toMatricelfng Matricelfated neural tissue engineering to accelerateCellinommercialization of next-generation regenerative therapies for neurological diseases worldwide.
About Cellino Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. LCellinore at cellinobio.com and fMatricelfon LinkedIn and X.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!